Disease Severity and Quality of Life in Patients with Idiopathic Pulmonary Fibrosis: A Cross-Sectional Analysis of the IPF-PRO Registry: Disease severity and quality of life in IPF

RECOMMENDED

Pulmonary Fibrosis

Hospital-Based Resource Use and Costs Among Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry

★ 1 Recommended by Dr Martin Frey, Faculty Member

Chest.

Fan Y, Bender SD, Conoscenti CS, Davidson-Ray L, Cowper PA, Palmer SM, de Andrade JA, IPF-PRO™ Registry investigators.

doi: 10.1016/j.chest.2019.12.041.

RECOMMENDED

Pulmonary Fibrosis

Implementation of guideline recommendations and outcomes in patients with idiopathic pulmonary fibrosis: Data from the IPF-PRO registry

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Respir Med

de Andrade JA, Kulkarni T, Neely ML, Hellkamp AS, Case AH, Guntupalli K, Bender S, Conoscenti CS, Snyder LD, IPF-PRO Registry investigators.

doi: 10.1016/j.rmed.2021.106637

RECOMMENDED

Pulmonary Fibrosis

Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Respir Res.

Holtze CH, Freiheit EA, Limb SL, Stauffer JL, Raimundo K, Pan WT, Flaherty KR, Kim HJ

doi: 10.1186/s12931-020-1315-4.

RECOMMENDED

Interstitial Lung DiseasePulmonary Fibrosis

Health-related quality of life of patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Eur Respir Rev

Cox IA, Borchers Arriagada N, de Graaff B, Corte TJ, Glaspole I, Lartey S, Walters EH, Palmer AJ

doi: 10.1183/16000617.0154-2020

Idiopathic pulmonary fibrosis in a Swiss interstitial lung disease reference centre

Swiss Med Wkly.

Guler S, Zumstein P, Berezowska S, Pöllinger A, Geiser T, Funke-Chambour M

doi: 10.4414/smw.2018.14577.

RECOMMENDED

Pulmonary Fibrosis

Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis

N Engl J Med.

Kolb M, Raghu G, Wells AU, Behr J, Richeldi L, Schinzel B, Quaresma M, Stowasser S, Martinez FJ; INSTAGE Investigators

doi: 10.1056/NEJMoa1811737.

Pulmonary Fibrosis

Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: a candidate gene sequencing study

Lancet Respir Med.

Dressen A, Abbas AR, Cabanski C, Reeder J, Ramalingam TR, Neighbors M, Bhangale TR, Brauer MJ, Hunkapiller J, Reeder J, Mukhyala K, Cuenco K, Tom J, Cowgill A, Vogel J, Forrest WF, Collard HR, Wolters PJ, Kropski JA, Lancaster LH, Blackwell TS, Arron JR, Yaspan BL

doi: 10.1016/S2213-

RECOMMENDED

Interstitial Lung DiseasePulmonary Fibrosis

Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry

Eur Respir J.

Behr J, Prasse A, Wirtz H, Koschel D, Pittrow D, Held M, Klotsche J, Andreas S, Claussen M, Grohé C, Wilkens H, Hagmeyer L, Skowasch D, Meyer JF, Kirschner J, Gläser S, Kahn N, Welte T, Neurohr C, Schwaiblmair M, Bahmer T, Oqueka T, Frankenberger M, Kreuter M

doi: 10.1183/13993003.02279-2019.

COMMENTED

Pulmonary Fibrosis

Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials

Lancet Respir Med.

Neighbors M, Cabanski CR, Ramalingam TR, Sheng XR, Tew GW, Gu C, Jia G, Peng K, Ray JM, Ley B, Wolters PJ, Collard HR, Arron JR

doi: 10.1016/

Related content

Hospital-Based Resource Use and Costs Among Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry

Implementation of guideline recommendations and outcomes in patients with idiopathic pulmonary fibrosis: Data from the IPF-PRO registry

Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry

Health-related quality of life of patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis

Idiopathic pulmonary fibrosis in a Swiss interstitial lung disease reference centre

Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis

Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: a candidate gene sequencing study

Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry

Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials